Last reviewed · How we verify
ACT-1014-6470
At a glance
| Generic name | ACT-1014-6470 |
|---|---|
| Sponsor | Idorsia Pharmaceuticals Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 (PHASE1)
- A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects (PHASE1)
- A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects (PHASE1)
- A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT-1014-6470 CI brief — competitive landscape report
- ACT-1014-6470 updates RSS · CI watch RSS
- Idorsia Pharmaceuticals Ltd. portfolio CI